Compare
Ocrevus vs. Ocrevus Zunovo

Ocrevus (ocrelizumab) is used to treat multiple sclerosis (MS) in adults. It can also treat certain children 10 years and older with relapsing-remitting MS. Ocrevus (ocrelizumab) is a type of monoclonal antibody. It's given as an infusion through the vein every 6 months at a medical center or clinic. A trained healthcare professional will help give Ocrevus (ocrelizumab) to you. Side effects can include a higher risk of infections and infusion reactions.

• All types of multiple sclerosis (MS) in adults
• Relapsing-remitting MS in children 10 years and older who weigh at least 55 lbs

• Upper respiratory tract infections (40%)
• Infusion reactions (34%)

• Infusion reactions
• Risk of serious infections
• Lower antibody levels
• Serious inflammation of the colon
• Liver damage
• Possible higher risk of cancer

Ocrevus Zunovo (ocrelizumab / hyaluronidase) is an injection that's given under the skin (subcutaneous). It's used to treat multiple sclerosis (MS) in adults. Ocrevus Zunovo is a monoclonal antibody. It also contains an enzyme called hyaluronidase that makes it easier for the medication to absorb through the skin. The injection is given every 6 months by a healthcare professional at a medical center or clinic. Side effects include injection-site reactions like pain, itching, and redness. You might also have a headache and feel nauseous.

• All types of multiple sclerosis (MS)

• Reaction at the injection site (e.g., redness, pain, swelling, itching; 50%)
• Other reaction related to the injection (e.g., flushing, nausea, headache; 12%)

• Injection reactions
• Risk of serious infections
• Lower antibody levels
• Serious inflammation of the colon
• Possible higher risk of cancer